Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Return on Equity (2021 - 2025)

SAB Biotherapeutics' Return on Equity history spans 5 years, with the latest figure at 0.3% for Q4 2025.

  • For Q4 2025, Return on Equity rose 74.0% year-over-year to 0.3%; the TTM value through Dec 2025 reached 0.3%, up 74.0%, while the annual FY2025 figure was 0.54%, 47.0% up from the prior year.
  • Return on Equity reached 0.3% in Q4 2025 per SABSW's latest filing, up from 0.48% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.15% in Q3 2021 to a low of 2.44% in Q2 2025.
  • Average Return on Equity over 5 years is 0.91%, with a median of 0.77% recorded in 2024.
  • The largest YoY upside for Return on Equity was 74bps in 2025 against a maximum downside of -163bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.47% in 2021, then crashed by -30bps to 0.61% in 2022, then crashed by -92bps to 1.16% in 2023, then rose by 11bps to 1.04% in 2024, then skyrocketed by 71bps to 0.3% in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Return on Equity are 0.3% (Q4 2025), 0.48% (Q3 2025), and 2.44% (Q2 2025).